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PREAMBLE
I t is essential that the medical profession play a central role in critically evaluating the evidence related to drugs, devices, and procedures for the detection, management, or prevention of disease. Properly applied, rigorous, expert analysis of the available data documenting absolute and relative benefits and risks of these therapies and procedures can improve outcomes and reduce costs of care by focusing resources on the most effective strategies. One important use of such data is the production of clinical practice guidelines which, in turn, can provide a foundation for a variety of other applications such as performance measures, appropriate use criteria, clinical decision support tools, and quality improvement tools.
The American College of Cardiology Foundation (ACCF) and the American Heart Association (AHA) have jointly engaged in the production of guidelines in the area of cardiovascular disease since 1980. The ACCF/AHA Task Force on Practice Guidelines is charged with developing, updating, and revising practice guidelines for cardiovascular diseases and procedures, and the Task Force directs and oversees this effort. Writing committees are charged with assessing the evidence as an independent group of authors to develop, update, or revise recommendations for clinical practice.
Experts in the subject under consideration have been selected from both organizations to examine subject-specific data and write guidelines in partnership with representatives from other medical practitioner and specialty groups. Writing committees are specifically charged to perform a formal literature review, weigh the strength of evidence for or against particular treatments or procedures, and include estimates of expected health outcomes where data exist. Patient-specific modifiers, comorbidities, and issues of patient preference that may influence the choice of tests or therapies are considered. When available, information from studies on cost is considered, but data on efficacy and clinical outcomes constitute the primary basis for recommendations in these guidelines.
The ACCF/AHA Task Force on Practice Guidelines makes every effort to avoid actual, potential, or perceived conflicts of interest that may arise as a result of industry relationships or personal interests among the writing committee. Specifically, all members of the writing committee, as well as peer reviewers of the document, are asked to disclose all current relationships and those 24 months prior to initiation of the writing effort that may be perceived as relevant. All guideline recommendations require a confidential vote by the writing committee and must be approved by a consensus of the members voting. Members who were recused from voting are noted on the title page of this document. Members must recuse themselves from voting on any recommendation where their relationships with industry (RWI) and other entities apply. If a writing committee member develops a new relationship with industry during his/her tenure, he/she is required to notify guideline staff in writing. These statements are reviewed by the Task Force on Practice Guidelines and all members during each conference call and/or meeting of the writing committee, updated as changes occur, and ultimately published as an appendix to the document. For detailed information regarding guideline policies and procedures, please refer to the methodology manual for ACCF/AHA Guideline Writing Committees. 1 RWI and other entities pertinent to this guideline for authors and peer reviewers are disclosed in Appendixes 1 and 2, respectively. Disclosure information for the ACCF/AHA Task Force on Practice Guidelines is also available online at http://www. acc.org/about/overview/ClinicalDocumentsTaskForces.cfm.
These practice guidelines are intended to assist healthcare providers in clinical decision making by describing a range of generally acceptable approaches for diagnosis, management, and prevention of specific diseases or conditions. Clinicians should consider the quality and availability of expertise in the area where care is provided. These guidelines attempt to define practices that meet the needs of most patients in most circumstances. The recommendations reflect a consensus after a thorough review of the available current scientific evidence and are intended to improve patient care. The Task Force recognizes that situations arise where additional data are needed to better inform patient care; these areas will be identified within each respective guideline when appropriate.
Patient adherence to prescribed and agreed upon medical regimens and lifestyles is an important aspect of treatment. Prescribed courses of treatment in accordance with these recommendations are effective only if they are followed. Because lack of patient understanding and adherence may adversely affect outcomes, physicians and other healthcare providers should make every effort to engage the patient's active participation in prescribed medical regimens and lifestyles.
If these guidelines are used as the basis for regulatory or payer decisions, the goal should be improvement in quality of care and aligned with the patient's best interest. The ultimate judgment regarding care of a particular patient must be made by the healthcare provider and the patient in light of all of the circumstances presented by that patient. Consequently, there are circumstances in which deviations from these guidelines are appropriate.
The guidelines will be reviewed annually by the ACCF/AHA Task Force on Practice Guidelines and considered current unless they are updated, revised, or withdrawn from distribution. The full-text guidelines are e-published in the April 6, 2010, issues of the Journal of the American College of Cardiology and Circulation. 1a
INTRODUCTION 1.Methodology and Evidence Review
The writing committee conducted a comprehensive search of the medical and scientific literature through the use of PubMed/MEDLINE. Searches were limited to publications written in the English language. Compiled reports were reviewed and additional articles were provided by committee members. Specifically targeted searches were conducted on the following subtopics: acute aortic dissection, ankylosing spondylitis, aortic dissection and litigation, aortic neoplasm, aortic tumors, Behçet disease, bicuspid aortic valve, calcified aorta, chronic dissection, coarctation of the aorta, D-dimer, dissecting aneurysm, Ehlers-Danlos syndrome, endovascular and aortic aneurysms, medial degeneration, porcelain aorta, giant cell arteritis, imaging and thoracic aortic disease, inflammatory disease, intramural hematoma, Loeys-Dietz syndrome, Marfan syndrome, Noonan syndrome, penetrating aortic ulcer, polycystic kidney disease, thoracic and aortic aneurysms, thoracic aortic disease and patient care, thoracic aortic disease and surgery, thoracic aorta and Kawasaki disease, Takayasu arteritis, thoracoabdominal and aorta or aortic disease, and Turner syndrome. More than 850 references were reviewed, with 830 used as the primary evidence base for the final guideline. The ACCF/AHA Task Force on Practice Guidelines methodology processes were followed to write the text and recommendations. In general, published manuscripts appearing in journals listed in Index Medicus were used as the evidence base. Published abstracts were used only for emerging information but were not used in the formulation of recommendations.
The committee reviewed and ranked evidence supporting current recommendations with the weight of evidence ranked as Level A if the data were derived from multiple randomized clinical trials or meta-analyses. The committee ranked available evidence as Level B when data were derived from a single randomized trial or nonrandomized studies. Evidence was ranked as Level C when the primary source of the recommendation was consensus opinion, case studies, or standard of care. In the narrative portions of these guidelines, evidence is generally presented in chronologic order of development. Studies are identified as observational, retrospective, prospective, or randomized. For certain conditions for which inadequate data are available, recommendations are based on expert consensus and clinical experience and are ranked as Level C. An analogous example is the use of penicillin for pneumococcal pneumonia, where there are no randomized trials and treatment is based on clinical experience. When recommendations at Level C are supported by historical clinical data, appropriate references (including clinical reviews) are cited if available. For issues where sparse data are available, a survey of current practice among the clinicians on the writing committee formed the basis for Level C recommendations and no references are cited. The schema for classification of recommendations and level of evidence is summarized in Table 1 , which also illustrates how the grading system provides an estimate of the size of the treatment effect and an estimate of the certainty of the treatment effect.
To provide clinicians with a comprehensive set of data, whenever possible, the exact event rates in various treatment arms of clinical trials are presented to permit calculation of the absolute risk difference (ARD), number needed to harm (NNH); the relative treatment effects are described either as odds ratio (OR), relative risk (RR), or hazard ratio (HR) depending on the format in the original publication. Along with all other point statistics, confidence intervals (CIs) for those statistics are added when available.
The writing committee recognized that the evidence base for this guideline is less robust in terms of randomized clinical trials than prior ACCF/AHA guidelines, particularly those focused on coronary artery disease (CAD) and Table 1 . Applying Classification of Recommendations and Level of Evidence *Data available from clinical trials or registries about the usefulness/efficacy in different subpopulations, such as sex, age, history of diabetes, history of prior myocardial infarction, history of heart failure, and prior aspirin use. A recommendation with Level of Evidence B or C does not imply that the recommendation is weak. Many important clinical questions addressed in the guidelines do not lend themselves to clinical trials. Even though randomized trials are not available, there may be a very clear clinical consensus that a particular test or therapy is useful or effective.
†In 2003, the ACCF/AHA Task Force on Practice Guidelines developed a list of suggested phrases to use when writing recommendations. All guideline recommendations have been written in full sentences that express a complete thought, such that a recommendation, even if separated and presented apart from the rest of the document (including headings above sets of recommendations), would still convey the full intent of the recommendation. It is hoped that this will increase readers' comprehension of the guidelines and will allow queries at the individual recommendation level.
heart failure. As the reader will discern, much of the evidence base for this topic consists of cohort studies and retrospective reviews, which largely emanate from centers with a specialized interest in specific types of thoracic aortic disease. The writing committee attempted to focus on providing the practitioner with recommendations for evaluation and treatment wherever possible and where controversy exists, identified as such in the text. The writing committee acknowledges the expertise of the highly experienced and effective practice guidelines staff of the ACCF and AHA. The writing committee chair also acknowledges the commitment and dedication of the diverse writing committee members who were able to put aside issues of specialty "turf" and focus on providing the medical community with a guideline aimed at optimal patient care.
Organization of the Writing Committee
The guideline was written by a committee comprised of experts in cardiovascular medicine, surgery, radiology, and nursing. For many of the previous ACCF/AHA practice guidelines, writing expertise has been available within these 2 organizations. Because of the broad scope and diversity of thoracic aortic diseases, as well as the specialists who treat such patients, the ACCF and AHA sought greater involvement from many specialty organizations. Most, but not all, specialty organizations that represent the major stakeholders caring for patients with thoracic aortic diseases provided writing committee members and financial support of the project, and they are recognized as marquee level partners with the ACCF and AHA. These organizations included the American Association for Thoracic Surgery (AATS), American College of Radiology (ACR), American Stroke Association (ASA), Society of Cardiovascular Anesthesiologists (SCA), Society for Cardiovascular Angiography and Interventions (SCAI), Society of Interventional Radiology (SIR), Society of Thoracic Surgeons (STS), and Society for Vascular Medicine (SVM). The American College of Emergency Physicians (ACEP) and the American College of Physicians (ACP) were also represented on the writing committee. Where additional expertise was needed, the scientific councils of the AHA were contacted for writing committee representatives. Representation was provided or facilitated by the Councils on Cardiovascular Nursing, Cardiovascular Surgery and Anesthesia, Cardiovascular Radiology and Intervention, and Clinical Cardiology, Council for High Blood Pressure Research, and Stroke Council.
Document Review and Approval
This document was reviewed by 3 outside reviewers nominated by the ACCF and 2 outside reviewers nominated by the AHA, as well as 1 or 2 reviewers from each of the following organizations: the AATS, ACP, ACEP, ACR, ASA, SCA, SCAI, SIR, STS, and the SVM. It was also reviewed by 6 individual content reviewers-2 content reviewers from the ACCF Catheterization Committee and 1 content reviewer from the ACCF Interventional Council. All reviewer RWI information was collected and distributed to the writing committee and is published in this document (see Appendix 2). This document was approved for publication by the governing bodies of the ACCF and the AHA; and the AATS, ACEP, ACR, ASA, SCA, SCAI, SIR, STS, and SVM and was endorsed by the North American Society for Cardiovascular Imaging.
Scope of the Guideline
The term thoracic aortic disease encompasses a broad range of degenerative, structural, acquired, genetic-based, and traumatic disease states and presentations. According to the Centers for Disease Control and Prevention death certificate data, diseases of the aorta and its branches account for 43 000 to 47 000 deaths annually in the United States. 2 The precise number of deaths attributable to thoracic aortic diseases is unclear. However, autopsy studies suggest that the presentation of thoracic aortic disease is often death due to aortic dissection (AoD) and rupture, and these deaths account for twice as many deaths as attributed to ruptured abdominal aortic aneurysms (AAAs). 3 The diagnosis of acute thoracic AoD or rupture is often difficult and delayed, and errors in diagnosis may account for deaths otherwise attributed to cardiac arrhythmia, myocardial infarction (MI), pulmonary embolism, or mesenteric ischemia.
Most patients with significant thoracic aortic disease will be directed to specialized practitioners and institutions. However, the importance of early recognition and prompt treatment and/or referral for a variety of thoracic aortic diseases by all healthcare professionals provides the rationale for this document. This guideline will provide the practitioner with a sufficient description of background information, diagnostic modalities, and treatment strategies so that appropriate care of these patients can be facilitated and better understood. The goal of this guideline is to improve the health outcomes and quality of life for all patients with thoracic aortic disease.
This guideline includes diseases involving any or all parts of the thoracic aorta with the exception of aortic valve diseases 4 and includes the abdominal aorta when contiguous thoracic aortic diseases are present. Specific disease states are described in the following sections and the reader is referred to the glossary of terminology in Section 1.5 for abbreviations used throughout the guideline.
Critical Issues
As the writing committee developed this guideline, several critical issues emerged:
• Thoracic aortic diseases are usually asymptomatic and not easily detectable until an acute and often catastrophic complication occurs. Imaging of the thoracic aorta with computed tomographic imaging (CT), magnetic resonance imaging (MR), or in some cases, echocardiographic examination is the only method to detect thoracic aortic diseases and determine risk for future complications.
• Radiologic imaging technologies have improved in terms of accuracy of detection of thoracic aortic disease. However, as the use of these technologies has increased, so also has the potential risk associated with repeated radiation exposure, as well as contrast medium-related toxicity. Whether these technologies should be used repeatedly as a widespread screening tool is discussed in the full-text document. In addition, the writing committee formulated recommendations on a standard reporting format for thoracic aortic findings as discussed in Section 4.
• Imaging for asymptomatic patients at high risk based on history or associated diseases is expensive and not always covered by payers.
• For many thoracic aortic diseases, results of treatment for stable, often asymptomatic, but high-risk conditions are far better than the results of treatment required for acute and often catastrophic disease presentations. Thus, the identification and treatment of patients at risk for acute and catastrophic disease presentations (eg, thoracic AoD and thoracic aneurysm rupture) prior to such an occurrence are paramount to eliminating the high morbidity and mortality associated with acute presentations.
• A subset of patients with acute AoD are subject to missed or delayed detection of this catastrophic disease state. Many present with atypical symptoms and findings, making diagnosis even more difficult. This issue has come under greater medical-legal scrutiny, and specific cases have been widely discussed in the public domain. Widespread awareness of the varied and complex nature of thoracic aortic disease presentations has been lacking, especially for acute AoD. Risk factors and clinical presentation clues are noted in Section 9. The collaboration and cosponsorship of multiple medical specialties in the writing of this guideline will provide unique opportunities for widespread dissemination of knowledge to raise the level of awareness among all medical specialties.
• There is rapidly accumulating evidence that genetic alterations or mutations predispose some individuals to aortic diseases. Therefore, identification of the genetic alterations leading to these aortic diseases has the potential for early identification of individuals at risk. In addition, biochemical abnormalities involved in the progression of aortic disease are being identified through studies of patients' aortic samples and animal models of the disease. 5, 6 The biochemical alterations identified in the aortic tissue have the potential to serve as biomarkers for aortic disease. Understanding the molecular pathogenesis may lead to targeted therapy to prevent aortic disease. Medical and gene-based treatments are beginning to show promise for reducing or delaying catastrophic complications of thoracic aortic diseases.
Glossary of Terms and Abbreviations Used Throughout the Guideline
Aneurysm (or true aneurysm): a permanent localized dilatation of an artery, having at least a 50% increase in diameter compared to the expected normal diameter of the artery in question. Although all 3 layers (intima, media, and adventitia) may be present, the intima and media in large aneurysms may be so attenuated that in some sections of the wall they are undetectable. Pseudoaneurysm (or false aneurysm): contains blood resulting from disruption of the arterial wall with extravasation of blood contained by periarterial connective tissue and not by the arterial wall layers. Such an extravascular hematoma that freely communicates with the intravascular space is also known as a pulsating hematoma. 7-9 Ectasia: arterial dilatation less than 150% of normal arterial diameter. Arteriomegaly: diffuse arterial dilatation involving several arterial segments with an increase in diameter greater than 50% by comparison to the expected normal arterial diameter. 
THE THORACIC AORTA
The thoracic aorta is divided into 4 parts: the aortic root (which includes the aortic valve annulus, the aortic valve cusps, and the sinuses of Valsalva); the ascending aorta (which includes the tubular portion of the ascending aorta beginning at the sinotubular junction and extending to the brachiocephalic artery origin); the aortic arch (which begins at the origin of the brachiocephalic artery, and is the origin of the head and neck arteries, coursing in front of the trachea and to the left of the esophagus and the trachea); and the descending aorta (which begins at the isthmus between the origin of the left subclavian artery and the ligamentum arteriosum and courses anterior to the vertebral column, and then through the diaphragm into the abdomen) (see Figure 1 ). The normal human adult aortic wall is composed of 3 layers, listed from the blood flow surface outward: Intima: Endothelial layer on a basement membrane with minimal ground substance and connective tissue. Media: Bounded by an internal elastic lamina, a fenestrated sheet of elastic fibers; layers of elastic fibers arranged concentrically with interposed smooth muscle cells; bounded by an external elastic lamina, another fenestrated sheet of elastic fibers. Adventitia: A resilient layer of collagen containing the vasa vasorum and nerves. Some of the vasa vasorum can penetrate into the outer third of the media.
THORACIC AORTIC HISTOPATHOLOGY 3.1. Atherosclerosis
A 1995 consensus document from the AHA defines the types and histological classes of atherosclerosis 10 (Figure 2 ).
Aneurysms and Dissections
Aortic aneurysm histopathology, more accurately termed medial degeneration, is characterized by disruption and loss of elastic fibers and increased deposition of proteoglycans.
SPECIAL ARTICLE
Typically, there are areas of loss of smooth muscle cells in the aortic media, but whether there is a total loss of smooth muscle cells in the aortic wall is not clear. Recent literature supports the presence of inflammatory cell infiltration in this disease. 11, 12 Aortic pathology associated with myosin heavy chain 11, smooth muscle (MYH11) and actin, alpha 2, smooth muscle aorta (ACTA2) mutations leading to ascending aortic aneurysms demonstrates a hyperplastic response by smooth muscle cells in the aortic media. The aortic media in aneurysm tissue taken from patients harboring mutations in these genes demonstrated focal hyperplasia associated with smooth muscle cells that were remarkable for a lack of structured orientation parallel to the lumen of the aorta, but instead, the smooth muscle cells were oriented randomly with respect to one another. 13, 14 Increased immunostaining for a subset of matrix metalloproteinases (MMPs) has been described in the media of thoracic aortic aneurysms, particularly MMP-2 and MMP-9. [15] [16] [17] [18] Immunostaining of aortic media from patients with Marfan syndrome has demonstrated increases of MMP-2 and MMP-9, which was associated with smooth muscle cells at the borders of areas of medial degeneration and on the surface of disrupted elastic fibers. Elevated MMP-2 and MMP-9 immunostaining has been demonstrated in ascending aneurysms from patients with either tricuspid or bicuspid aortic valves 16, 18 and inconsistently in ascending aortic tissue from patients with tricuspid aortic valves. 17 These 2
MMPs are known to have elastolytic activity. Variable expression of MMPs and tissue inhibitors of MMPs has also been demonstrated in aortic tissue of patients with Marfan syndrome versus patients without Marfan syndrome. 19 Although accumulation of proteoglycans in the aortic media is another consistent finding in thoracic aortic aneurysms, no studies have determined why this accumulation occurs or whether these are causative in nature.
Vasculitis and Inflammatory Diseases
Giant cell arteritis and Takayasu arteritis share important features 19a with T-cell clonal expansion suggesting an antigenic response. An adventitial inflammatory response is marked by augmented cytokine and MMP production causing granuloma formation, which causes vessel destruction. 19b Behçet disease affects both arteries and veins of all sizes. Table 2 Class IIa
RECOMMENDATIONS FOR AORTIC IMAGING TECHNIQUES TO DETERMINE THE PRESENCE AND PROGRESSION OF THORACIC AORTIC DISEASE Class I

Measurements of aortic diameter should be taken at reproducible anatomic landmarks, perpendicular to the axis of blood flow, and reported in a clear and consistent format (see
If clinical information is available, it can be useful to relate aortic diameter to the patient's age and body size (see Tables 3 and 4). (Level of Evidence: C)
Definitive identification or exclusion of thoracic aortic disease or one of its anatomic variants requires dedicated aortic imaging. Selection of the most appropriate imaging study may depend on patient related factors (ie, hemodynamic stability, renal function, contrast allergy) and institutional capabilities (ie, rapid availability of individual imaging modalities, state of the technology, and imaging specialist expertise). Consideration should be given to patients with borderline abnormal renal function (serum creatinine greater than 1.8 to 2.0 mg/dL)-specifically, the tradeoffs between the use of iodinated intravenous contrast for CT and the possibility of contrast-induced nephropathy, and gadolinium agents used with MR and the risk of nephrogenic systemic fibrosis. 22 Radiation exposure should be minimized. 21, [23] [24] [25] [26] The risk of radiation-induced malignancy is the greatest in neonates, children, and young adults. 21 Generally, above the age of 30 to 35 years, the probability of radiation-induced malignancy decreases substantially. 20, 21 For patients who require repeated imaging to follow an aortic abnormality, MR may be preferred to CT. MR may require sedation due to longer examination times and tendency for claustrophobia.
CT as opposed to echocardiography can best identify thoracic aortic disease, as well as other disease processes that can mimic aortic disease, including pulmonary embolism, pericardial disease, and hiatal hernia. After intervention or open surgery, CT is preferred to detect asymptomatic postprocedural leaks or pseudoaneurysms because of the presence of metallic closure devices and clips.
CT and MR measure external aortic diameter, whereas echocardiography measures internal aortic diameter. Lumen size may not accurately reflect external diameter due to intraluminal clot, wall inflammation, or AoD. A recent refinement in the CT measurement of aortic size examines the vessel size using a centerline of flow, which reduces the error of tangential measurement and allows true short-axis measurement of aortic diameter. Essential element of aortic imaging reports are listed in Table 2 . 
Chest X-Ray
Routine chest x-ray may occasionally detect abnormalities of aortic contour or size that require definitive aortic imaging. Chest x-ray often serves as a part of the evaluation of patients with potential acute AoD, primarily to identify other causes of patient's symptoms, but also as a screening test to identify findings due to a dilated aorta or bleeding.
Computed Tomographic Imaging
CT scanning has several advantages, including nearuniversal availability; the ability to image the entire aorta, including lumen, wall, and periaortic regions; to identify anatomic variants and branch vessel involvement; to distinguish among types of acute aortic syndromes (ie, intramural hematoma [IMH], penetrating atherosclerotic ulcer [PAU], and acute AoD); and the short time required to complete the imaging process and the 3-dimensional data. Electrocardiogram-gated techniques have made it possible to generate motion-free images of the aortic root and coronary arteries, similar to coronary CT angiographic imaging. Reports of newer-generation multidetector helical CT scanners show sensitivities of up to 100% and specificities of 98% to 99%. 29 -32 The sequence for a CT performed in the potential setting of acute AoD generally would include a noncontrast study to detect subtle changes of IMH, followed by a contrast study to delineate the presence and extent of the dissection flap, identify regions of potential malperfusion, and demonstrate contrast leak indicating rupture. Imaging of the vascular tree from the thoracic inlet to the pelvis, including the iliac and femoral arteries, provides sufficient information to plan surgical or endovascular treatment, if needed. Prompt interpretation and communication of findings to the appropriate treating physicians are essential in the acute setting. (For further information on technique parameters and anatomic coverage, see the online-only Data Supplement.)
Magnetic Resonance Imaging
MR has been shown to be very accurate in the diagnosis of thoracic aortic disease, with sensitivities and specificities that are equivalent to or may exceed those of CT and transesophageal echocardiogram (TEE). 30, [35] [36] [37] [38] [39] Advantages of MR include the ability to identify anatomic variants of AoD (IMH and PAU), assess branch artery involvement, and diagnose aortic valve pathology and left ventricular dysfunction without exposing the patient to either radiation or iodinated contrast. Disadvantages include prolonged duration of imaging acquisition during which the patient is inaccessible to care providers; inability to use gadolinium contrast in patients with renal insufficiency; contraindication in patients with claustrophobia, metallic implants or pacemakers, and lack of widespread availability on an emergency basis.
Echocardiography
Echocardiography can detect the presence of aortic enlargement and associated cardiac pathology that suggests the underlying etiology of the aortic disease (eg, bicuspid aortic valve). For AoD (Figure 3 ), one of the major limitations of both transthoracic echocardiogram (TTE) and TEE is the frequent appearance of artifacts that mimic a dissection flap ( Figure 4 ). These usually arise from a mirror image or reverberation artifact that appears as a mobile linear echodensity overlying the aortic lumen. It is therefore essential that the echocardiographer make certain to distinguish true dissection flaps from such artifacts. There are several syndromic and nonsyndromic genetic conditions that are associated with the development of thoracic aortic aneurysms and present with dissections at smaller diameters than usual. The following recommendations focus on these specific conditions, including Marfan syndrome, Loeys-Dietz syndrome, Turner syndrome, bicuspid aortic valve, and other genetic mutations (TGFBR1, TGFBR2, FBN1, ACTA2, COL3A1, MYH11) (see Tables 5 and 6 ). A substantial proportion of Ehlers-Danlos syndrome patients who do not have the vascular form also have aortic root dilatation but the progression of this dilatation to AoD is rare. 42, 49 Similarly, patients with congenital contractural arachnodactyly or Beals syndrome due to mutations in FBN2 have had aortic root enlargement without documented progression to dissection. 50, 51 There are other genetic syndromes that have multiple reports or documentation of thoracic aortic aneurysms leading to Type A dissections. There are multiple case reports of AoD in patients with autosomal dominant polycystic kidney disease. 52, 53 Although AoD is a complication of autosomal dominant polycystic kidney disease, it is less common than cerebral aneurysms leading to subarachnoid hemorrhage in this population. There is insufficient information to gauge the value of routine or screening imaging for these patients.
Similar to autosomal dominant polycystic kidney disease, there are multiple reports in the literature of patients with Noonan syndrome experiencing AoDs. 54 -56 The value of imaging or routine monitoring of these patients is unknown. A review of 200 patients with Alagille syndrome also identified thoracic aortic disease in a small subset of these patients. 57 6. RECOMMENDATIONS FOR FAMILIAL THORACIC AORTIC ANEURYSMS AND DISSECTIONS Class I 1. Aortic imaging is recommended for first-degree relatives of patients with thoracic aortic aneurysm and/or dissection to identify those with asymptomatic disease. 58 7 ). This process should include specific questions about medical history, family history, and pain features as well as a focused examination to identify findings that are associated with aortic dissection, including: a. High-risk conditions and historical features (see Table 8 ). 59 
. All patients presenting with acute neurological complaints should be questioned about the presence of chest, back, and/or abdominal pain and checked for peripheral pulse deficits as patients with dissection-related neurological pathology are less likely to report thoracic pain than the typical aortic dissection patient. 83 (Level of Evidence: C)
These recommendations provide guidance to improve more prompt diagnosis of acute AoD (Figure 7 ). The true incidence of acute AoD is difficult to define as AoD can be rapidly fatal and when patients expire prior to hospitalization, death may be erroneously attributed to another cause. Acute AoD is frequently missed on initial presentation and early mortality among this group may be misclassified as nondissection related. Classes of intimal tears are described in Figure 8 . The DeBakey and Stanford Classifications of AoD are pictured in Figure 9 . There is no unanimity as to which classification system should be universally used. Class III
INITIAL EVALUATION AND MANAGEMENT OF ACUTE THORACIC AORTIC DISEASE
A negative chest x-ray should not delay definitive aortic imaging in patients determined to be high risk for aortic dissection by initial screening. (Level of Evidence: C)
Recommendations for Diagnostic Imaging Studies
Class I
Selection of a specific imaging modality to identify or exclude aortic dissection should be based on patient variables and institutional capabilities, including immediate availability. (Level of Evidence: C) 2. If a high clinical suspicion exists for acute aortic dissection but initial aortic imaging is negative, a second imaging study should be obtained. 85 (Level of Evidence: C)
Recommendations for Initial Management
See Figure 10 .
Class I
1. Initial management of thoracic aortic dissection should be directed at decreasing aortic wall stress by controlling heart rate and blood pressure as follows: 
a. In the absence of contraindications, intravenous beta blockade should be initiated and titrated to a target heart rate of 60 beats per minute or less. (Level of Evidence: C) b. In patients with clear contraindications to beta blockade, nondihydropyridine calcium channel--blocking agents should be utilized as an alternative for rate control. (Level of Evidence: C) c. If systolic blood pressures remain greater than 120 mm Hg after adequate heart rate control has been obtained, then angiotensin-converting enzyme inhibitors and/or other vasodilators should be administered intravenously to further reduce blood pressure that maintains adequate endorgan perfusion. (Level of Evidence: C) d. Beta blockers should be used cautiously in the setting of acute aortic regurgitation because they will block the compensatory tachycardia. 4 (Level of Evidence: C)
Class III
Vasodilator therapy should not be initiated prior to rate control so as to avoid associated reflex tachycardia that may increase aortic wall stress, leading to propagation or expansion of a thoracic aortic dissection. (Level of Evidence: C)
Recommendations for Definitive Management
See Figures 9 and 11 . Table 9 ). (Level of Evidence: C) 14 The clinical response to angiotension receptor blockers (losartan in 17 patients and irbesartan in 1 patient) were evaluated in pediatric patients with Marfan syndrome with severe aortic root enlargement. The mean (ϮSD) rate of change in aortic root diameter decreased significantly from 3.54Ϯ2.87 mm/y during previous medical therapy to 0.46Ϯ0.62 mm/y during angiotension receptor blocker therapy (PϽ0.001). The deviation of aortic root enlargement from normal, as expressed by the rate of change in z scores, was reduced by a mean difference of 1.47 z scores/y (95% CI 0.70 to 2.24, PϽ0.001) after the initiation of angiotension receptor blocker therapy. The sinotubular junction showed a reduced rate of change in diameter during angiotension receptor blocker therapy (PϽ0.05), whereas the distal ascending aorta was not affected by angiotension receptor blocker therapy.
Class I
Urgent surgical consultation should be obtained for all patients diagnosed with thoracic aortic dissection regardless of the anatomic location (ascending versus descending) as soon as the diagnosis is made or highly suspected. (Level of Evidence: C) 2. Acute thoracic aortic dissection involving the ascending aorta should be urgently evaluated for emergent surgical repair because of the high risk of associated life-threatening complications such as rupture. 75 (Level of Evidence: B) 3. Acute thoracic aortic dissection involving the descending aorta should be managed medically unless lifethreatening complications develop (ie, malperfusion syndrome, progression of dissection, enlarging aneurysm, inability to control blood pressure or symptoms). 80,92-96 (Level of Evidence: B)
RECOMMENDATION FOR SURGICAL INTERVENTION FOR ACUTE THORACIC AORTIC DISSECTION Class I
For patients with ascending thoracic aortic dissection, all aneurysmal aorta and the proximal extent of the dissection should be resected. A partially dissected aortic root
RECOMMENDATION FOR MEDICAL TREATMENT OF PATIENTS WITH THORACIC AORTIC DISEASES Class I
Stringent control of hypertension, lipid profile optimization, smoking cessation, and other atherosclerosis risk-reduction measures should be instituted for patients with small aneurysms not requiring surgery, as well as for patients who are not considered surgical or stent graft candidates (see
Recommendation for Dyslipidemia Class IIa
Treatment with a statin to achieve a target LDL cholesterol of less than 70 mg/dL is reasonable for patients with a coronary heart disease risk equivalent such as noncoronary atherosclerotic disease, atherosclerotic aortic aneurysm, and coexistent
Statins
Diehm N, Decker G, Katzen B, et al 106 A nonrandomized propensity-score-adjusted study of statin use effect on long-term mortality of patients after endovascular repair of AAA (731 patients) or TAA (59 patients) was done. Statin use was associated with decreased long-term mortality in patients with AAA (adjusted HR 0.613, 95% CI 0.379 to 0.993, Pϭ0.047), but not for patients with TAA (adjusted HR 1.795, 95% CI 0.147 to 21.942, Pϭ0.647).
AAA indicates abdominal aortic aneurysm; CI, confidence interval; SD, standard deviation; and TAA, thoracic aortic aneurysm. thoracic aorta, usually with the elephant trunk procedure (see Figure 14 ). 133 The mean rate of growth for all thoracic aortic aneurysms is approximately 1 mm/y, but that growth rate increases with increasing aneurysm diameter. Growth rates tend to be faster for aneurysms involving the descending versus the ascending aorta, for dissected versus nondissected aortas, for those with Marfan syndrome versus those without, 206 and for those with bicuspid versus tricuspid aortic valves. 207 Establishing clear lifestyle goals for patients with thoracic aortic disease is important in improving long-term health and reducing the risk of complications. There are no outcomes data, and scant data of any variety for that matter, to indicate how much exercise is safe or beneficial for patients with thoracic aortic disease. However, aerobic exercise, sometimes referred to as dynamic exercise, is associated with only a modest increase in mean arterial pressure, 209 and AoD rarely occurs during aerobic exercise. Consequently, most experts believe that aerobic exercise, particularly when heart rate and blood pressure are well controlled with medications, is beneficial overall. Nevertheless, if patients wish to engage in vigorous aerobic exercise, such as running or basketball, one might consider performing a symptom limited stress test to ensure that the patient does not have a hypertensive response to exercise.
RECOMMENDATIONS FOR OPEN SURGERY
Conversely, with isometric exercise, there is a significant increase in mean arterial pressure. When the Valsalva maneuver is used for the lifting of heavy weights, there is a superimposed increase in intrathoracic pressure, followed by a dramatic increase in systemic arterial pressure, 209 with systolic pressures reaching 300 mm Hg or more. 210 As a result, most experts believe that heavy weight lifting or competitive athletics involving isometric exercise may trigger AoD and/or rupture and that such activities should be avoided. 211 Working with patients on an individualized basis to streamline these goals based on insufficient data can be challenging. For patients who are very much interested in maintaining some sort of weight lifting program, choosing sets of repetitive light weights appears to make more sense than permitting heavy weight lifting. 209 
TUMORS OF THE THORACIC AORTA
Neoplasms of the thoracic aorta are usually secondary and related to contiguous spread of adjacent primary malignancies, particularly lung and adjacent primary malignancies or subsequent metastases, particularly lung and esophagus. [212] [213] [214] [215] Primary neoplasms of the thoracic aorta are rare. 213 Metastatic disease is often demonstrated at the time of diagnosis of primary aortic neoplasms. Symptoms may include malaise, fatigue, weight loss and nausea or the occurrence of distal arterial embolization (with histopathologic examination showing neoplasm, or identified by imaging techniques during a search for an embolic source). 216 -218 AoD may originate in the area of the neoplasm or the aortic occlusion. 219 Resection and reconstruction of the segment of aorta containing the neoplasm have been described, but because most patients present with metastatic disease, overall prognosis is poor. 220 
RECOMMENDATIONS FOR QUALITY ASSESSMENT AND IMPROVEMENT FOR THORACIC AORTIC DISEASE Class I
1. Hospitals that provide regional care for patients with acute sequelae of thoracic aortic disease (eg, procedures for thoracic aortic dissection and rupture) should participate in standardized quality assessment and improvement activities, including thoracic aortic disease registries. Such activities should include periodic measurement and regional/national Patients with acute aortic syndromes may require transfer to specialized institutions. Ideally, the communications between institutions will completely and accurately portray the condition of the patient including items listed in Table  12 . members with industry and other entities that were reported orally at the initial writing committee meeting and updated in conjunction with all meetings and conference calls of the writing committee during the document development process. It does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% or more of the voting stock or share of the business entity, or ownership of $10 000 or more of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. A relationship is considered to be modest if it is less than significant under the preceding definition. Relationships noted in this table are modest unless otherwise noted. *Significant (greater than $10 000) relationship. 
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